Tagrisso shows Real-World promise in korean lung cancer patients

NCT ID NCT03918304

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This study looked at how safe and effective the drug Tagrisso (osimertinib) is for people with a certain type of advanced lung cancer in everyday medical practice. Over 900 patients in Korea took part, and researchers tracked side effects and how well the drug controlled the cancer. The goal was to confirm that the drug works as expected outside of strict clinical trial settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Busan, South Korea
Research Site

Chungcheongbuk-do, South Korea
Research Site

Daegu, South Korea
Research Site

Daejeon, South Korea
Research Site

Gangwon State, South Korea
Research Site

Gyeonggi-do, South Korea
Research Site

Incheon, South Korea
Research Site

Jeollabuk-do, South Korea
Research Site

Jeollanam-do, South Korea
Research Site

Seoul, South Korea

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG